{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:17:16Z","timestamp":1793866636048,"version":"4.6.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T00:00:00Z","timestamp":1525651200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003197","name":"AIFA","doi-asserted-by":"crossref","award":["FARM9LBBBL"],"award-info":[{"award-number":["FARM9LBBBL"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00228-018-2467-8","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T06:06:28Z","timestamp":1525673188000},"page":"1061-1070","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation"],"prefix":"10.1007","volume":"74","author":[{"name":"on behalf of the Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8601-1899","authenticated-orcid":false,"given":"Rosanna Irene","family":"Comoretto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersilia","family":"Lucenteforte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mugelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Trifir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Cascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Roberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Chinellato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Filippelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Corrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,7]]},"reference":[{"key":"2467_CR1","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1161\/01.CIR.0000140263.20897.42","volume":"110","author":"DM Lloyd Jones","year":"2004","unstructured":"Lloyd Jones DM, Wang TJ, Leip EP et al (2004) Lifetime risk for development of atrial fibrillation the Framingham heart study. Circulation 110:1042\u20131046","journal-title":"Circulation"},{"key":"2467_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel W (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 22:983\u2013988","journal-title":"Stroke"},{"key":"2467_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0002-9343(02)01236-6","volume":"113","author":"S Stewart","year":"2002","unstructured":"Stewart S, Hart CL, Hole DJ, McMurray JJ (2002) A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew\/paisley study. Am J Med 113:359\u2013364","journal-title":"Am J Med"},{"key":"2467_CR4","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jacc.2010.05.028","volume":"56","author":"R Marinigh","year":"2010","unstructured":"Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA (2010) Age as a risk factor for stroke in atrial fibrillation patients: Implications for thromboprophylaxis. J Am Coll Cardiol 56:827\u2013837","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"2467_CR5","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1161\/CIRCULATIONAHA.108.190748","volume":"118","author":"RO Bonow","year":"2008","unstructured":"Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS, 2006 Writing Committee Members, American College of Cardiology\/American Heart Association Task Force (2008) Focused update incorporated into the ACC\/AHA 2006 guidelines for the management of patients with valvular heart disease. Circulation 118(15):e523\u2013e661","journal-title":"Circulation"},{"issue":"6 suppl","key":"2467_CR6","doi-asserted-by":"publisher","first-page":"454S","DOI":"10.1378\/chest.08-0658","volume":"133","author":"C Kearon","year":"2008","unstructured":"Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ (2008) Antithrombotic therapy for venous thromboembolic disease. Chest 133(6 suppl):454S\u2013545S","journal-title":"Chest"},{"key":"2467_CR7","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857\u2013867","journal-title":"Ann Intern Med"},{"key":"2467_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-9560-12-20","volume":"12","author":"G Teklay","year":"2014","unstructured":"Teklay G, Shiferaw N, Legesse B, Bekele ML (2014) Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study. Thromb J 12:20","journal-title":"Thromb J"},{"key":"2467_CR9","first-page":"23","volume":"8","author":"M Rikala","year":"2016","unstructured":"Rikala M, Kastarinen H, Tiittanen P, Huupponen R, Korhonen MJ (2016) Natural history of bleeding and characteristics of early bleeders among warfarin initiators \u2013 a cohort study in Finland. Clin Epidemiol 8:23\u201335","journal-title":"Clin Epidemiol"},{"key":"2467_CR10","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u20131151","journal-title":"N Engl J Med"},{"key":"2467_CR11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM, the ROCKET AF Steering Committee (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883\u2013891","journal-title":"N Engl J Med"},{"key":"2467_CR12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992","journal-title":"N Engl J Med"},{"key":"2467_CR13","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, \u0160pinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, ENGAGE AF-TIMI 48 Investigators (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093\u20132104","journal-title":"N Engl J Med"},{"key":"2467_CR14","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","volume":"165","author":"AM Holbrook","year":"2005","unstructured":"Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165:1095\u20131106","journal-title":"Arch Intern Med"},{"issue":"2","key":"2467_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ccl.2007.12.010","volume":"26","author":"LG Jacobs","year":"2008","unstructured":"Jacobs LG (2008) Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Cardiol Clin 26(2):157\u2013167","journal-title":"Cardiol Clin"},{"key":"2467_CR16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","volume":"130","author":"JL Halperin","year":"2014","unstructured":"Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA, ROCKET AF Steering Committee and Investigators, on behalf of the ROCKET AF Steering Committee and Investigators (2014) Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 130:138\u2013146","journal-title":"Circulation"},{"key":"2467_CR17","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ahj.2004.11.015","volume":"149","author":"JP DiMarco","year":"2005","unstructured":"DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, Rosenfeld LE, Mitrani G, Nemeth M, AFFIRM Investigators (2005) AFFIRM investigators. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Am Heart J 149:650\u2013656","journal-title":"Am Heart J"},{"issue":"15","key":"2467_CR18","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, for the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group et al (2000) Meta-analysis of Observational Studies in Epidemiology. A Proposal for Reporting. JAMA 283(15):2008\u20132012","journal-title":"JAMA"},{"issue":"2","key":"2467_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.18773\/austprescr.2015.016","volume":"38","author":"PA Tideman","year":"2015","unstructured":"Tideman PA, Tirimacco R, St John A, Roberts GW (2015) How to manage warfarin therapy. Aust Prescr 38(2):44\u201348","journal-title":"Aust Prescr"},{"issue":"2","key":"2467_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/DCC.0000000000000022","volume":"33","author":"SW Darnell","year":"2014","unstructured":"Darnell SW, Davis SC, Whitcomb JJ, Manfredi JA, McLaurin BT (2014) Bleeding risk factors affecting warfarin therapy in the elderly with atrial fibrillation. Dimens Crit Care Nurs 33(2):57\u201363","journal-title":"Dimens Crit Care Nurs"},{"issue":"6","key":"2467_CR21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.4158\/EP13093.RA","volume":"19","author":"L Tomisti","year":"2013","unstructured":"Tomisti L, Del Re M, Bartalena L et al (2013) Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature. Endocr Pract 19(6):1043\u20131049","journal-title":"Endocr Pract"},{"issue":"6","key":"2467_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3810\/pgm.2012.11.2608","volume":"124","author":"AJ Greenspon","year":"2012","unstructured":"Greenspon AJ (2012) A review of oral anticoagulants in patients with atrial fibrillation. Postgrad Med 124(6):7\u201316","journal-title":"Postgrad Med"},{"issue":"1","key":"2467_CR23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1590\/S1679-45082012000100024","volume":"10","author":"JS Teles","year":"2012","unstructured":"Teles JS, Fukuda EY, Feder D (2012) Warfarin: pharmacological profile and drug interactions with antidepressants. Einstein (Sao Paulo) 10(1):110\u2013115","journal-title":"Einstein (Sao Paulo)"},{"key":"2467_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"2467_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"2467_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith DG, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"issue":"3","key":"2467_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36(3):1\u201348 \n                    https:\/\/cran.r-project.org\/web\/packages\/metafor\/index.html\n                    \n                  . Accessed 30 Jan 2017","journal-title":"J Stat Softw"},{"key":"2467_CR28","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.jclinepi.2008.01.006","volume":"61","author":"ME Charlson","year":"2008","unstructured":"Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP (2008) The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 61:1234\u20131240","journal-title":"J Clin Epidemiol"},{"key":"2467_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/oxfordjournals.epirev.a036144","volume":"16","author":"SS Coughlin","year":"1994","unstructured":"Coughlin SS, Benichou J, Weed DL (1994) Attributable risk in case-control studies. Epidemiol Rev 16:51\u201364","journal-title":"Epidemiol Rev"},{"key":"2467_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2105\/AJPH.88.1.15","volume":"88","author":"B Rockhill","year":"1998","unstructured":"Rockhill B, Newman B, Weinberg C (1998) Use and misuse of population attributable fractions. Am J Public Health 88:15\u201319","journal-title":"Am J Public Health"},{"key":"2467_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0020-7101(95)01152-8","volume":"41","author":"R Bender","year":"1996","unstructured":"Bender R (1996) Calculating confidence intervals for summary measures of individual curves via nonlinear regression models. Int J Biomed Comput 41:13\u201318","journal-title":"Int J Biomed Comput"},{"key":"2467_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/archinte.165.2.189","volume":"165","author":"M Battistella","year":"2005","unstructured":"Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A (2005) Risk of upper gastrointestinal haemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 165:189\u2013192","journal-title":"Arch Intern Med"},{"issue":"6","key":"2467_CR33","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/01.jcp.0000186869.67418.bc","volume":"25","author":"PA Kurdyak","year":"2005","unstructured":"Kurdyak PA, Juurlink DN, Kopp A, Herrmann N, Mamdani MM (2005) Antidepressants, warfarin, and the risk of hemorrhage. J Clin Psychopharmacol 25(6):561\u2013564","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"2467_CR34","doi-asserted-by":"publisher","first-page":"369.e9","DOI":"10.1016\/j.amjmed.2006.06.008","volume":"120","author":"JD Douketis","year":"2007","unstructured":"Douketis JD, Melo M, Bell CM, Mamdani MM (2007) Does statin therapy decrease the risk for bleeding in patients who are receiving warfarin? Am J Med 120(4):369.e9\u2013369e14","journal-title":"Am J Med"},{"key":"2467_CR35","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/clpt.2008.150","volume":"84","author":"H Schelleman","year":"2008","unstructured":"Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S (2008) Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther 84:581\u2013588","journal-title":"Clin Pharmacol Ther"},{"key":"2467_CR36","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/pds.1737","volume":"18","author":"SM Wallerstedt","year":"2009","unstructured":"Wallerstedt SM, Gleerup H, Sundstr\u00f6m A, Stigendal L, Ny L (2009) Risk of clinically relevant bleeding in warfarin-treated patients influence of SSRI treatment. Pharmacoepidemiol Drug Saf 18:412\u2013416","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2467_CR37","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/archinternmed.2010.37","volume":"170","author":"HD Fischer","year":"2010","unstructured":"Fischer HD, Juurlink DN, Mamdani MM, Kopp A, Laupacis A (2010) Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. Arch Intern Med 170:617\u2013621","journal-title":"Arch Intern Med"},{"key":"2467_CR38","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","volume":"170","author":"ML Hansen","year":"2010","unstructured":"Hansen ML, S\u00f8rensen R, Clausen MT, Fog-Petersen ML, Rauns\u00f8 J, Gadsb\u00f8ll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstr\u00f8m SZ, Poulsen HE, K\u00f8ber L, Torp-Pedersen C (2010) Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170:1433\u20131441","journal-title":"Arch Intern Med"},{"key":"2467_CR39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.amjmed.2009.07.020","volume":"123","author":"H Schelleman","year":"2010","unstructured":"Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S (2010) Fibrate\/statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med 123:151\u2013157","journal-title":"Am J Med"},{"key":"2467_CR40","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/FTD.0b013e318224996e","volume":"33","author":"KA Cochran","year":"2011","unstructured":"Cochran KA, Cavallari LH, Shapiro NL, Bishop JR (2011) Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit 33:433\u2013438","journal-title":"Ther Drug Monit"},{"key":"2467_CR41","doi-asserted-by":"publisher","first-page":"e21447","DOI":"10.1371\/journal.pone.0021447","volume":"6","author":"H Schelleman","year":"2011","unstructured":"Schelleman H, Brensinger CM, Bilker WB, Hennessy S (2011) Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study. PLoS One 6:e21447","journal-title":"PLoS One"},{"key":"2467_CR42","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/pds.2219","volume":"20","author":"AI Vitry","year":"2011","unstructured":"Vitry AI, Roughead EE, Ramsay EN, Preiss AK, Ryan P, Gilbert AL, Caughey GE, Shakib S, Esterman A, Zhang Y, McDermott RA (2011) Major bleeding risk associated with warfarin and co-medications in the elderly population. Pharmacoepidemiol Drug Saf 20:1057\u20131063","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2467_CR43","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.amjmed.2011.08.014","volume":"125","author":"J Baillargeon","year":"2012","unstructured":"Baillargeon J, Holmes HM, Lin YL, Raji MA, Sharma G, Kuo YF (2012) Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med 125:183\u2013189","journal-title":"Am J Med"},{"key":"2467_CR44","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/clpt.2012.171","volume":"92","author":"D Pincus","year":"2012","unstructured":"Pincus D, Gomes T, Hellings C, Zheng H, Paterson JM, Mamdani MM, Juurlink DN (2012) A population-based assessment of the drug interaction between levothyroxine and warfarin. Clin Pharmacol Ther 92:766\u2013770","journal-title":"Clin Pharmacol Ther"},{"key":"2467_CR45","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.clinthera.2012.05.008","volume":"34","author":"DC Suh","year":"2012","unstructured":"Suh DC, Nelson WW, Choi JC, Choi I (2012) Risk of hemorrhage and treatment costs associated with warfarin drug interactions in patients with atrial fibrillation. Clin Ther 34:1569\u20131582","journal-title":"Clin Ther"},{"key":"2467_CR46","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.amjcard.2013.03.051","volume":"112","author":"J Lam","year":"2013","unstructured":"Lam J, Gomes T, Juurlink DN, Mamdani MM, Pullenayegum EM, Kearon C, Spencer FA, Paterson M, Zheng H, Holbrook AM (2013) Hospitalization for hemorrhage among warfarin recipients prescribed amiodarone. Am J Cardiol 112:420\u2013423","journal-title":"Am J Cardiol"},{"key":"2467_CR47","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1177\/1060028013500940","volume":"47","author":"AD Mosholder","year":"2013","unstructured":"Mosholder AD, Racoosin JA, Young S, Wernecke M, Shoaibi A, MaCurdy TE, Worrall C, Kelman JA (2013) Bleeding events following concurrent use of warfarin and oseltamivir by Medicare beneficiaries. Ann Pharmacother 47:1420\u20131428","journal-title":"Ann Pharmacother"},{"key":"2467_CR48","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.amjmed.2014.01.044","volume":"127","author":"MA Lane","year":"2014","unstructured":"Lane MA, Zeringue A, McDonald JR (2014) Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans. Am J Med 127:657\u2013663","journal-title":"Am J Med"},{"key":"2467_CR49","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.amjcard.2014.05.037","volume":"114","author":"GR Quinn","year":"2014","unstructured":"Quinn GR, Singer DE, Chang Y, Go AS, Borowsky LH, Udaltsova N, Fang MC (2014) Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. Am J Cardiol 114:583\u2013586","journal-title":"Am J Cardiol"},{"key":"2467_CR50","first-page":"135","volume-title":"Pharmacoepidemiology","author":"SR Ahmad","year":"2006","unstructured":"Ahmad SR, Goetsch RA, Marks NS (2006) Spontaneous reporting in the United States. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Chichester, pp 135\u2013159","edition":"4"},{"key":"2467_CR51","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2165\/00002018-200225060-00010","volume":"25","author":"AC Egberts","year":"2002","unstructured":"Egberts AC, Meyboom RH, van Puijenbroek EP (2002) Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf 25:453\u2013458","journal-title":"Drug Saf"},{"key":"2467_CR52","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72:905\u2013908","journal-title":"Br J Clin Pharmacol"},{"key":"2467_CR53","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N (2007) Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 30:891\u2013898","journal-title":"Drug Saf"},{"key":"2467_CR54","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/sim.2739","volume":"26","author":"DB Rubin","year":"2007","unstructured":"Rubin DB (2007) The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med 26:20\u201336","journal-title":"Stat Med"},{"key":"2467_CR55","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1345\/aph.1G408","volume":"40","author":"L Boulanger","year":"2006","unstructured":"Boulanger L, Hauch O, Friedman M, Foster T, Dixon D, Wygant G, Menzin J (2006) Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation. Ann Pharmacother 40:1024\u20131029","journal-title":"Ann Pharmacother"},{"key":"2467_CR56","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1093\/eurheartj\/ehr134","volume":"32","author":"M Wieloch","year":"2011","unstructured":"Wieloch M, Sj\u00e4lander A, Frykman V et al (2011) Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 32:2282\u20132289","journal-title":"Eur Heart J"},{"key":"2467_CR57","doi-asserted-by":"publisher","first-page":"E121","DOI":"10.1503\/cmaj.121218","volume":"185","author":"T Gomes","year":"2013","unstructured":"Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Hellings C, Juurlink DN (2013) Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ 185:E121\u2013E127","journal-title":"CMAJ"},{"key":"2467_CR58","doi-asserted-by":"publisher","first-page":"e003839","DOI":"10.1136\/bmjopen-2013-003839","volume":"4","author":"AM Gallagher","year":"2014","unstructured":"Gallagher AM, van Staa TP, Murray-Thomas T, Schoof N, Clemens A, Ackermann D, Bartels DB (2014) Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes. BMJ Open 4:e003839","journal-title":"BMJ Open"},{"key":"2467_CR59","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/0470842555","volume-title":"Pharmacoepidemiology","author":"BL Strom","year":"2000","unstructured":"Strom BL (2000) Overview of automated databases in pharmacoepidemiology. In: Strom BL, Kimmel SE, Hennessy S (eds) Pharmacoepidemiology, 3rd edn. Wiley-Blackwell, Oxford, pp 219\u2013222","edition":"3"},{"key":"2467_CR60","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/0003-4819-146-4-200702200-00007","volume":"146","author":"F Dentali","year":"2007","unstructured":"Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA (2007) Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 146:278\u2013288","journal-title":"Ann Intern Med"},{"key":"2467_CR61","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/archinternmed.2010.37","volume":"170","author":"HD Fischer","year":"2010","unstructured":"Fischer HD, Juurlink DN, Mamdani M, Kopp A, Laupacis A (2010) Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents. Arch Intern Med 170:617\u2013621","journal-title":"Arch Intern Med"},{"key":"2467_CR62","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/clinids\/22.2.251","volume":"22","author":"DS Israel","year":"1996","unstructured":"Israel DS, Stotka J, Rock W, Sintek CD, Kamada AK, Klein C, Swaim WR, Pluhar RE, Toscano JP, Lettieri JT, Heller AH, Polk RE (1996) Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. Clin Infect Dis 22:251\u2013256","journal-title":"Clin Infect Dis"},{"key":"2467_CR63","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1111\/j.1538-7836.2008.03196.x","volume":"6","author":"N Abdelmalik","year":"2008","unstructured":"Abdelmalik N, Ruhe HG, Barwari K et al (2008) Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism. J Thromb Haemost 6:2168\u20132174","journal-title":"J Thromb Haemost"},{"key":"2467_CR64","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1006\/phrs.2001.0817","volume":"43","author":"VL Serebruany","year":"2001","unstructured":"Serebruany VL, Gurbel PA, O\u2019Connor CM (2001) Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res 43:453\u2013462","journal-title":"Pharmacol Res"},{"key":"2467_CR65","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1136\/bmj.323.7314.655","volume":"323","author":"C Walraven van","year":"2001","unstructured":"van Walraven C, Mamdani MM, Wells PS, Williams JI (2001) Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 323:655\u2013658","journal-title":"BMJ"},{"key":"2467_CR66","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/archinte.163.1.59","volume":"163","author":"SO Dalton","year":"2003","unstructured":"Dalton SO, Johansen C, Mellemkjaer L et al (2003) Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 163:59\u201364","journal-title":"Arch Intern Med"},{"key":"2467_CR67","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1001\/archinte.164.21.2367","volume":"164","author":"WE Meijer","year":"2004","unstructured":"Meijer WE, Heerdink ER, Nolen WA et al (2004) Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 164:2367\u20132370","journal-title":"Arch Intern Med"},{"key":"2467_CR68","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1160\/TH03-05-0330","volume":"91","author":"E Maurer-Spurej","year":"2004","unstructured":"Maurer-Spurej E, Pittendreigh C, Solomons K (2004) The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 91:119\u2013128","journal-title":"Thromb Haemost"},{"key":"2467_CR69","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/JCP.0b013e3181abdfd7","volume":"29","author":"A Ataoglu","year":"2009","unstructured":"Ataoglu A, Canan F (2009) Mean platelet volume in patients with major depression: effect of escitalopram treatment. J Clin Psychopharmacol 29:368\u2013371","journal-title":"J Clin Psychopharmacol"},{"key":"2467_CR70","doi-asserted-by":"publisher","unstructured":"Szummer K, Gasparini A, Eliasson S, Arnlov J, Qureshi AR, Barany P, et al (2017) Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction. J Am Heart Assoc 6. \n                    https:\/\/doi.org\/10.1161\/JAHA.116.004925","DOI":"10.1161\/JAHA.116.004925"},{"key":"2467_CR71","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.clinthera.2014.07.016","volume":"36","author":"FE Cotte","year":"2014","unstructured":"Cotte FE, Benhaddi H, Duprat-Lomon I, Doble A, Marchant N, Letierce A et al (2014) Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries. Clin Ther 36:1160\u20131168","journal-title":"Clin Ther"},{"key":"2467_CR72","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1161\/HYPERTENSIONAHA.114.04858","volume":"65","author":"G Corrao","year":"2015","unstructured":"Corrao G, Mancia G (2015) Generating evidence from computerized healthcare utilization databases. Hypertension 65:490\u2013498","journal-title":"Hypertension"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2467-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2467-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2467-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T12:12:58Z","timestamp":1557231178000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2467-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,7]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["2467"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2467-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,7]]},"assertion":[{"value":"12 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"EL received research support from the Italian Agency of Drug (AIFA) that is not related to this study. AM received research support from the Italian Agency of Drug (AIFA), the Italian Ministry for University and Research (MIUR), Gilead, and Menarini. In the last 2\u00a0years, he received personal fees as speaker\/consultant from Menarini Group, IBSA, Molteni, Angelini and Pfizer Alliance. None of these is related to this study. GT leads an academic pharmacoepidemiology team which runs project that are sponsored by pharmaceutical companies and that are not related to the topic of the paper. GC received research support from European Community (EC), European Medicine Agency (EMA), Italian Agency of Drug (AIFA), High Health Institute (ISS), Ministry for Health, and University and Research. He took part to a variety of projects that were funded by pharmaceutical companies (i.e., Novartis, GSK, Roche, AMGEN, and BMS). He also received honoraria as member of Advisory Board from Roche. None of these is related to this study. RIC, FR, LS, SC, GR, AC, and AF declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}